Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  206.29
+1.02 (0.50%)
AAPL  274.18
+8.00 (3.00%)
AMD  209.56
+12.97 (6.59%)
BAC  50.14
-0.93 (-1.83%)
GOOG  308.57
-3.12 (-1.00%)
META  634.77
-2.48 (-0.39%)
MSFT  386.52
+2.05 (0.53%)
NVDA  190.33
-1.22 (-0.63%)
ORCL  145.10
+3.79 (2.68%)
TSLA  403.08
+3.25 (0.81%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.